Page 10 - Dr Reddy’s Laboratories

From Nestle India to Maruti Suzuki, impact of Covid-19 on earning estimates

Given the huge hit from lockdown, it is not surprising that 44 of the 80 companies have seen sharp cuts ranging 10% to 72%

MARKET WRAP: Sensex ends 114 pts higher, ITC surges 7%; India VIX drops 8%

All that happened in the markets today

Market Ahead, May 20: All you need to know before the opening bell

Reliance Industries will be in focus today as its mega rights issue opens today and closes on June 3

Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit

The plant is one of the company's three units that were served a warning letter in November 2015 for not following the prescribed operational and manufacturing quality standards

Google sees jump in cloud infra use as India stays at home during lockdown

We're pushing limits to bring tech to every user, says Google Cloud India head Karan Bajwa

Diversified model, US outlook to help Dr Reddy's stock trade better

The company has multiple growth engines given its focus on India/emerging markets and limited competition products in the US

Wockhardt tanks 5% after it sells domestic branded ops to Dr Reddy's Labs

The deal, which could fetch a consideration amount of Rs 1,850 crore, is expected to close in the first quarter of financial year 2020-21, Wockhardt added.

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Deal would help Wockhardt focus on international operations, novel pipeline R&D

Dr Reddy's posts Rs 570-cr net loss due to heavy impairment charge

Firm takes a Rs 1,110 crore hit with generic versions of its Nuvaring drug hitting the market; financial results run completely contra to analyst expectations

Dr Reddy's Labs nears 2-year high, regains Rs 50,000 crore m-cap

In the first 11 trading days of the current calendar year, Dr Reddy's has outperformed the market by surging 6 per cent on expectations of earnings improvement.

Pharma shares in focus; Dr Reddy's, Divi's, Granules hit 52-week highs

Lupin, Sun Pharmaceutical, Cadila Healthcare, Aarti Drugs and Aurobindo Pharma were up in the range of 2 per cent to 3 per cent.

Dr Reddy's gets nod for amalgamation of Dr Reddy's Holdings into company

21,026 votes, which accounted for the rest 0.02 per cent, were posted against the resolution, it added

Dr Reddy's reaping benefits of domestic market focus, outperforms peers

Firm has outperformed domestic pharma market in 7 of last 8 quarters

Amneal Pharma beats Dr Reddy's in launching limited-competition drug

Amneal's EluRyng is the first generic version of this low competition drug, which the company plans to launch this month

Dr Reddy's launches cancer treatment drug Bortezomib in the US market

Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals

Dr Reddy's Labs extends gains for second straight day, hits 33-month high

Analysts at SBICAP Securities upgraded the stock with 'buy' rating and target price of Rs 3,200 per share

Dr Reddy's gives part manufacturing to China partners to tap local market

The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's

Exposure to US market causing constant FDA scrutiny for big drug firms

Dr Reddy's was in the news for falling short of expectations during routine audits conducted by the US drug regulator

Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad

According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact

Dr Reddy's enters India's nutrition segment with a drink for diabetics

Dr Reddy's 'Celevida' is formulated to have high protein, high fibre and slowly digested carbohydrates